Skip to main content
Article
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
The New England Journal of Medicine (2017)
  • Philip Mease, University of Washington
  • Stephen Hall, Monash University
  • Oliver FitzGerald, University College Dublin
  • Désirée van der Heijde, Leiden University Medical Center
  • Joseph F. Merola, Brigham and Women's Hospital
  • Francisco Avila-Zapata
  • Dorota Cieślak
  • Daniela Graham, Pfizer
  • Cunshan Wang, Pfizer
  • Sujatha Menon, Pfizer
  • Thijs Hendrikx, Pfizer
  • Keith S. Kanik, Pfizer
Publication Date
October 19, 2017
DOI
10.1056/NEJMoa1615975
Citation Information
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, et al.. "Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis." The New England Journal of Medicine Vol. 377 Iss. 16 (2017) p. 1537 - 1550
Available at: http://works.bepress.com/philip-mease/27/